We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Epidermal Growth Factor (EGF) Antibodies|
|Conjugate||This EGF antibody is conjugated to Biotin Alternatives|
Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-EGF AntibodyTarget Details EGF Application Details Handling Images
|Specificity||This antibody reacts with Epidermal Growth Factor (hEGF).|
|Immunogen||Highly pure (>98%) recombinant hEGF (human EGF).|
Target Details EGFProduct Details anti-EGF Antibody Application Details Handling Images back to top
|Alternative Name||EGF (EGF Antibody Abstract)|
|Background||Epidermal growth factor (EGF) has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells. The EGF precursor is believed to exist as a membrane bound molecule which is proteolytically cleaved to generate the 53 amino acid peptide hormone that stimulates cells to divide. EGF exerts its actions by binding to the EGFR, a 170 kDa protein. Epidermal growth factor (EGF) is a key growth factor regulating cell survival. Through its binding to cell surface receptors, EGF activates an extensive network of signal transduction pathways that include activation of the PI3K/AKT, RAS/ERK and JAK/STAT pathways. Because of its key role in driving the proliferation of cells, EGFR is a target of several anti-cancer drugs currently in development.Synonyms: Epidermal growth factor, HOMG4, Pro-epidermal growth factor, URG, Urogastrone|
|Research Area||Cancer, Growth Factors|
|Pathways||NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation|
Application DetailsProduct Details anti-EGF Antibody Target Details EGF Handling Images back to top
ELISA: To detect hEGF by direct ELISA (using 100 l/well antibody solution) this antibodycan be used at a concentration of 0.15-0.30 μg/mL. Used in conjunction with compatiblesecondary reagents, allows the detection of at least 0.2 ng/well of recombinant hEGF. Western Blot: To detect hEGF by Western Blot analysis this antibody can be used at aconcentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagentsthe detection limit for recombinant hEGF is 1.5-3.0 ng/lane, under either reducing ornon-reducing conditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-EGF Antibody Target Details EGF Application Details Images back to top
|Reconstitution||Restore in sterile PBS containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL.|
|Buffer||PBS, pH 7.2 without preservatives.|
|Handling Advice||Avoid repeated freezing and thawing. Centrifuge vial prior to opening!|
|Storage||4 °C/-20 °C|
|Storage Comment||Store the antibody prior to reconstitution at -20 °C. Following reconstitution the antibody can be stored at 2-8 °C for one month or at -20 °C for longer.|